CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT04282174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies
Study identification
- NCT ID
- NCT04282174
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Baptist Health South Florida
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Bone Marrow Transplant Procedure
- Busulfan Drug
- CliniMACS Device
- Cyclophosphamide Drug
- Fludarabine Drug
- Hyperfractionated Total Body Irradiation Drug
- Melphalan Drug
- Thiotepa Drug
Procedure · Drug · Device
Eligibility (public fields only)
- Age range
- Up to 74 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2022
- Primary completion
- Feb 28, 2030
- Completion
- Feb 28, 2030
- Last update posted
- Sep 26, 2022
2022 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Miami Cancer Institute at Baptist Health, Inc. | Miami | Florida | 33176 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04282174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 26, 2022 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04282174 live on ClinicalTrials.gov.